论文部分内容阅读
目的:研究肝癌,肺癌患者凝血机能的改变。材料和方法:对50例拟行介入治疗的肝癌,肺癌患者介入治疗前行体外血栓形成试验,血小板粘附、聚集试验,及纤维蛋白原,血粘度,红细胞偶然性聚集性及刚性等指标的检测(并选100例正常献血员作为正常对照)。结果:肝癌,肺癌患者体外血栓长度,湿重,干重均较正常人增加(P<0.001);血小板粘附率,聚集率均较正常增高;全血粘度,红细胞聚集指数,刚性指数均有明显增高;纤维蛋白原定量亦增加(P<0.001)。结论:肝癌、肺癌患者介入治疗前血液即处于高凝状态,其有明显的血栓形成趋势,这就为肝癌、肺癌患者在介入治疗过程中配合抗凝及活血化阏治疗提供了理论依据,同时也是评价介入治疗疗效的一个重要指标。
Objective: To study the changes of coagulation function in patients with liver cancer and lung cancer. Materials and methods: 50 cases of hepatocellular carcinoma to be treated with interventional treatment, lung cancer patients undergoing in vitro thrombosis test, platelet adhesion, aggregation test, and fibrinogen, blood viscosity, and occasional aggregation of red blood cells and rigidity indicators (And select 100 normal blood donors as normal controls). Results: The in vitro thrombus length, wet weight and dry weight of liver cancer patients and lung cancer patients were all higher than those of normal people (P<0.001). The platelet adhesion rate and aggregation rate were all higher than normal; the whole blood viscosity, erythrocyte aggregation index and rigidity index were all increased. Significantly higher; fibrinogen quantification also increased (P <0.001). Conclusion: The blood of patients with hepatocellular carcinoma and lung cancer before interventional treatment is in a hypercoagulable state, which has a clear tendency of thrombosis. This provides a theoretical basis for the treatment of liver cancer and lung cancer patients in the interventional treatment with anticoagulation and blood circulation therapy. It is also an important indicator to evaluate the efficacy of interventional treatment.